Our Audience
Our audience is made up of the teams that buy from suppliers like you. They work across antibody engineering, conjugation chemistry, process and analytical development, CMC, and safety assessment, developing and manufacturing ADCs and other bioconjugates. They register with BioInsights for practical answers to the problems your products and services solve.
We put your content in front of them on the topics they already come to us for. Our editors are subject specialists who work with leading experts every day, and they shape your material into the formats these readers use.
Matched to the problem you solve: recent coverage includes site-specific conjugation for bispecific and dual-payload ADCs, enzymatic and peptide-based conjugation platforms, how linker and conjugation chemistry shape toxicity, and translating novel-target ADCs against treatment-resistant cancers. You reach the readers working on the problem your product addresses.
Targeted by topic, not just job title: every reader registers against at least one specific topic. You choose the problem area, and we reach the people working on it.
The credibility of an expert-led platform: the journal is shaped by senior editors and an advisory board that includes a chief medical officer at a global pharmaceutical company, an ADC technology head who contributed to two approved ADCs, leads of bioconjugation process development, ADC platforms, and CMC at global pharma, and academic leaders in bioconjugation chemistry. Your content carries the BioInsights name.
Attention you can see: a median of 254 registrations per webinar and 46 minutes average viewing time. Registrations and performance are reported to you.
